Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Cerebral Adrenoleukodystrophy

Neurological & Neuromuscular

Cerebral Adrenoleukodystrophy (CALD) Clinical Trials

Also called CALD, cerebral ALD, childhood cerebral ALD, X-linked adrenoleukodystrophy cerebral form

Cerebral adrenoleukodystrophy is caused by mutations in the ABCD1 gene on the X chromosome, which encodes a peroxisomal membrane transporter essential for importing very-long-chain fatty acids (VLCFAs) into peroxisomes for beta-oxidation. When this transporter is defective, VLCFAs accumulate in tissues throughout the body, but the most devastating effects occur in the brain. In the cerebral form, VLCFA accumulation triggers a catastrophic inflammatory demyelination of cerebral white matter, typically beginning in the parietal-occipital region and spreading anteriorly.

In plain words, cerebral adrenoleukodystrophy is a genetic brain disease where the body cannot break down certain fats, so they build up. In the brain the buildup sets off an immune attack that quickly damages the protective coating around nerves.

Get an email when new Cerebral Adrenoleukodystrophy trials open or the FDA decides. Get alerts

Cerebral Adrenoleukodystrophy

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 8 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines1

Skysona

Cerebral Adrenoleukodystrophy has 1 FDA-approved medicine, 8 open or active clinical trials (6 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Cerebral Adrenoleukodystrophy

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Cerebral Adrenoleukodystrophy

The disease progression in the cerebral form is rapid and relentless once inflammatory demyelination begins. Boys who were previously developing normally begin losing cognitive and motor function over months, progressing to a vegetative state and death, usually within 2-5 years of symptom onset without treatment. Hematopoietic stem cell transplant (HSCT) can halt progression if performed early, before significant neurological damage has occurred.

Keep reading about Cerebral Adrenoleukodystrophy

The gene therapy Skysona (elivaldogene autotemcel), from bluebird bio (renamed Genetix Biotherapeutics in 2025), received FDA accelerated approval in September 2022 for boys 4 to 17 with early, active cerebral ALD. Since August 2025 its label limits it to boys without an available HLA-matched stem cell donor and carries a strengthened boxed warning for blood cancer, which the label reports in 10 of 67 treated trial patients (15%).

In September 2026 the European Commission approved leriglitazone (Nezglyal), a daily medicine taken by mouth from Minoryx and its partner Neuraxpharm, for boys 2 to 12 with cerebral ALD whose brain lesions do not light up with gadolinium contrast on MRI. It is not approved in the U.S. Newborn screening that measures C26:0-lysophosphatidylcholine (C26:0-LPC), a marker of very-long-chain fatty acid buildup, in the heel-prick dried blood spot is now the standard for early detection, and serial MRI monitoring of at-risk boys enables treatment before irreversible damage occurs.

What are the symptoms of Cerebral Adrenoleukodystrophy?

These are common symptoms of Cerebral Adrenoleukodystrophy, and how strong they are varies from person to person.

  • Learning difficulties and declining school performance
  • Vision problems or progressive vision loss
  • Behavioral changes, irritability, and social withdrawal
  • Loss of coordination and balance
  • Decline in previously learned skills like writing and speaking
  • Progressive neurological decline including seizures and hearing loss

Who gets Cerebral Adrenoleukodystrophy?

Almost exclusively affects males due to X-linked inheritance. Cerebral form most commonly appears between ages 4 and 10. Females who carry one mutated ABCD1 gene may develop milder symptoms (adrenomyeloneuropathy) later in life. Newborn screening is now mandated in most U.S. states, enabling earlier detection.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Cerebral Adrenoleukodystrophy?

There is currently 1 FDA-approved medication for Cerebral Adrenoleukodystrophy.

elivaldogene autotemcel
Genetix Biotherapeutics (formerly bluebird bio)
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Cerebral Adrenoleukodystrophy treatment

Charity funds and drugmaker programs for Cerebral Adrenoleukodystrophy, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · United Leukodystrophy Foundation
    Hultman Memorial Fund fund
    Open

    Pays for: Expenses directly related to the affected family member, based on demonstrated hardship (per 12 months), up to $500 per year.

    The foundation says: “Applications are reviewed on a rolling basis as funding is available.”
Status as each foundation showed it on November 16, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Cerebral Adrenoleukodystrophy, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Cerebral Adrenoleukodystrophy

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Cerebral Adrenoleukodystrophy resources

Reputable organizations and medical references for learning more about Cerebral Adrenoleukodystrophy, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Cerebral Adrenoleukodystrophy

Use this Cerebral Adrenoleukodystrophy clinical trial finder to see the 6 studies recruiting patients and 2 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 1 tests a treatment and 7 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

8 active trials worldwide
Filter:
Sort:
RecruitingPatient registry covering many conditionsRecently updatedNCT03047369

The Myelin Disorders Biorepository Project

Sponsor: Children's Hospital of Philadelphia · Biogen + 5 more

The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, havin...

Ages not specified
Started Dec 2016Updated 1 week agoEst. Dec 2030 (~4 years)
Not yet recruitingTreatment trialRecently updatedNCT03727555

IT and IV Lentiviral Gene Therapy for X-ALD

Intervention: Intrathecal and intravenous LV gene therapy

Sponsor: Shenzhen Geno-Immune Medical Institute

This is a Phase I/II clinical trial of gene therapy for treating X-linked adrenoleukodystrophy using a high-safety, high-efficiency, self-inactivating lentiviral vector (LV) TYF-ABCD1 to functionally correct the defective gene. The objectives are to evaluate the safety and effica...

Ages 1 Year to 60 Years1 location
Expected to start Jun 2027Updated 2 weeks agoEst. May 2028 (~1y 6m)
RecruitingObservational study, no treatment givenRecently updatedNCT04675749

Quality of Life in Women With X-linked Adrenoleukodystrophy

Sponsor: Leipzig University Medical Center

X-linked adrenoleukodystrophy (X-ALD) is a hereditary white matter disorder caused by mutations in the ABCD1 gene leading to disturbances in the metabolism of fatty acids. This results in an accumulation of very long chain fatty acids (VLCFA) in the cells of the body causing dama...

Ages 18 Years+1 location
Started Dec 2019Updated 2 months agoEst. Jan 2028 (~1y 1m)
RecruitingObservational study, no treatment givenNo updates in a whileNCT03789721

Adrenoleukodystrophy National Registry Study

Intervention: Medical Record Abstraction, Biospecimen Sample Collection

Sponsor: Masonic Cancer Center, University of Minnesota

The aim of this registry to understand the natural history and disease progression in ALD and potentially develop bio-markers using the biospecimens collected using this registry.

Ages not specified1 location
Started May 2019Updated 6 months agoEst. Feb 2030 (~3y 3m)
RecruitingObservational study, no treatment givenHasn't posted an update in over a yearNCT06224413

A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel

Intervention: No Intervention

Sponsor: Genetix Biotherapeutics Inc.

The main aim of this study is to assess and describe the safety outcomes, including newly diagnosed malignancies, of patients with CALD treated with eli-cel in the post-marketing setting (tradename Skysona) and to describe major functional disability (MFD)-free survival over time...

Ages not specified3 locations
Started Mar 2024Updated 1 year agoEst. Dec 2047 (~21y 1m)
Find Cerebral Adrenoleukodystrophy trials near you, ranked by distance →
Active trial locations23 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+15 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Cerebral Adrenoleukodystrophy trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Cerebral Adrenoleukodystrophy foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Cerebral Adrenoleukodystrophy patient communities

Facebook groups, Reddit communities and YouTube channels where Cerebral Adrenoleukodystrophy patients, caregivers and advocacy groups talk.

Companies developing Cerebral Adrenoleukodystrophy treatments

Drugmakers that list Cerebral Adrenoleukodystrophy in their rare disease portfolio, 3 in all.

Questions people ask about Cerebral Adrenoleukodystrophy